Aridis Pharmaceuticals, Inc. signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc. (MappBio), a privately-owned leading developer of novel pharmaceuticals for the prevention and treatment of infectious diseases with a focus on unmet needs in global health and biodefense. Aridis and MappBio have committed to work exclusively with each other to expeditiously complete definitive licensing agreements MappBio's pan-Ebola and pan-Marburg mAb programs are currently in Phase 1 clinical studies and both products have shown best-in-class protection against live virus challenges in non-human primates. The Strategic National Stockpile is a federally funded program that acquires, stores, and distributes medical countermeasures in the event of a public health emergency.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.06 USD | -3.23% | 0.00% | -14.41% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.41% | 2.97M | |
+9.29% | 114B | |
+11.35% | 104B | |
-13.84% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.22% | 17.89B | |
+7.68% | 14.28B | |
+34.47% | 12.55B |
- Stock Market
- Equities
- ARDS Stock
- News Aridis Pharmaceuticals, Inc.
- Aridis Pharmaceuticals, Inc. Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical